Relaxane claims supported – NAD
This article was originally published in The Tan Sheet
Indigene Pharmaceuticals was able to support claims that its dietary supplement Relaxane relieves stress symptoms, the National Advertising Division concludes Dec 20. NAD evaluated three claims, including one that the product "is designed to provide stress relief and address multiple symptoms of stress." In support of its claims, the firm presented three clinical studies as well as two post-marketing surveys. NAD concluded it was "satisfied that the challenged advertising clearly conveys that Relaxane is for, and has been tested for, relief and alleviation of the symptoms associated with stress"...
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.